Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
about
Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitorsFactors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastasesABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor modelRegulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders.Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.Bayesian approach to estimate AUC, partition coefficient and drug targeting index for studies with serial sacrifice design.Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.Molecularly targeted therapies for recurrent glioblastoma: current and future targets.The effect of AZD2171- or sTRAIL/Apo2L-loaded polylactic-co-glycolic acid microspheres on a subcutaneous glioblastoma model.Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas.
P2860
Q28236180-C59B59C5-9A73-4941-AA2A-2305C6518ED6Q33942964-628E261F-2708-4E9E-8B40-D1857121CAE8Q35171274-92A735B6-A5EE-4485-BB5F-FA778CAF28FBQ36186193-8BF9AC58-0215-474F-A7EB-9C9EEF3A2102Q36378047-A6AE9393-43E3-4949-8D78-518386721BC9Q36717122-51981CA7-6A7D-4ACA-84C3-068F2E703917Q37331814-08D7C971-67B5-4FEB-9EF6-B90707116798Q37620062-87C7069E-A55D-4F06-B8F7-3E96A8AD5E34Q38233105-FAB5FBBD-2682-44E5-82EB-78AE6AE3C932Q38260539-088D1F47-D98A-4ABB-B21B-79B61F3A4431Q38272728-702E66C4-684F-42D1-A8DE-FA190BDE6F8CQ38867453-4B302F33-D8F1-44CB-B5CF-62489B7A0177Q39013294-6A529537-1AE5-4F4E-8DBD-DB07A44DB540Q43989660-F44A5E8B-D93C-466A-AA8F-876D6BFD0256Q48389089-23CF0F80-EB49-46AD-81CA-672CD394BAF3Q50857354-8849E3BF-F240-4869-A45E-A576789E0EC8
P2860
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
@ast
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
@en
type
label
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
@ast
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
@en
prefLabel
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
@ast
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
@en
P2093
P2860
P356
P1476
Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
@en
P2093
Sagar Agarwal
Tianli Wang
William F Elmquist
P2860
P304
P356
10.1124/JPET.111.190488
P407
P577
2012-02-08T00:00:00Z